Grant: Collaborative Research and Development Grants
University of Alberta
$35,520.00
In vitro methods to optimize inhalable nanoparticles
FY 2009-10
Summary
Today there is only limited information available about the therapeutic efficacy, interaction, toxicity of nano-sized delivery systems with lung epithelia cells and alveolar macrophages. A mechanistic assessment of the different effects an active principle (e.g. drug), excipients (e.g. matrix material) or a nanoparticle and a combination of all of them as a drug delivery system needs to be performed.
The aim of this grant is to study the mechanistic details of the effects of nano-sized pharmaceutical materials and their excipients with lung epithelia cells and macrophages. This will include the following objectives: 1) Synthesis and characterization of nanoparticles with different sizes and surface properties. 2) Evaluation of the intrinsic toxicity of nanoparticles and excipients using lung epithelia cells and macrophages. 3) Evaluation of secondary toxicity effects triggered by macrophages on other lung epithelium cells. 4) Systematic evaluation of translocation/permeability of nanoparticles and coated nanoparticles with lung mono layers.
The expected outcome of this research is the development of in vitro assessment techniques to predict the efficiency, toxicity and dosing margins of nano-sized materials in the alveolar region. The mechanistic investigation of these interactions will be used I the future to predict the in vivo behavior of pulmonary drug delivery systems. This will be the basis to develop optimization strategies of inhalable nanoparticles.
Program
Collaborative Research and Development Grants
Recipient
Location
Alberta, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data
As published
Application id
372421-2008
Name nom
Loebenberg, Raimar
Department département
Pharmacy and Pharmaceutical Science, Faculty of
Organization id
9
Institution établissement
University of Alberta
Province en
Alberta
Province fr
Alberta
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2009
Competition year année de concours
2008
Award amount
35520
Program id
CRDPJ
Program nane en
Collaborative Research and Development Grants
Program name fr
Subventions de recherche et développement coopérative
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
96
Committee name en
RPP Internal Decision Cttee
Committee name fr
Cté de décision interne - PPR
Area of application code
1211
Area of application group en
Advancement of knowledge
Area of application group fr
Avancement des connaissances
Area of application en
Medical and health sciences
Area of application fr
Sciences médicales et de la santé
Research subject code
6400
Research subject group en
Life sciences research related to human health and disease
Research subject group fr
Sciences de la vie liées à la santé publique et aux maladies humaines
Research subject en
Life sciences research related to human health and disease
Research subject fr
Sciences de la vie liées à la santé publique et aux maladies humaines
Partie
1
Nb partie
2
Application title
In vitro methods to optimize inhalable nanoparticles
Keyword
NA
Application summary
Today there is only limited information available about the therapeutic efficacy, interaction, toxicity of nano-sized delivery systems with lung epithelia cells and alveolar macrophages. A mechanistic assessment of the different effects an active principle (e.g. drug), excipients (e.g. matrix material) or a nanoparticle and a combination of all of them as a drug delivery system needs to be performed.
The aim of this grant is to study the mechanistic details of the effects of nano-sized pharmaceutical materials and their excipients with lung epithelia cells and macrophages. This will include the following objectives: 1) Synthesis and characterization of nanoparticles with different sizes and surface properties. 2) Evaluation of the intrinsic toxicity of nanoparticles and excipients using lung epithelia cells and macrophages. 3) Evaluation of secondary toxicity effects triggered by macrophages on other lung epithelium cells. 4) Systematic evaluation of translocation/permeability of nanoparticles and coated nanoparticles with lung mono layers.
The expected outcome of this research is the development of in vitro assessment techniques to predict the efficiency, toxicity and dosing margins of nano-sized materials in the alveolar region. The mechanistic investigation of these interactions will be used I the future to predict the in vivo behavior of pulmonary drug delivery systems. This will be the basis to develop optimization strategies of inhalable nanoparticles.